(MENAFN) A new study published by Oxford University has revealed that hormonal contraception, including progesterone-only contraceptive pills, increases the risk of breast cancer by 25%. The research suggests that women with a family history of breast cancer should avoid taking these pills due to the possible increased risk of the disease. The study found that women taking a progesterone-only pill carried a slightly higher risk of breast cancer at 26%. The absolute excess risk of breast cancer associated with either type of oral contraceptive will be smaller in women who use it at younger ages.
The study evaluated the records of 9,498 women in the UK aged 20 to 49 diagnosed with breast cancer from 1996 to 2017 and compared their results with a control group of 18,171 closely matched women without a breast cancer diagnosis. The researchers found that women taking a combined contraceptive pill of estrogen and progesterone were 23% more at risk from breast cancer, while those taking a progesterone-only pill (POP) carried a slightly higher risk, at 26%. The study also found that a progesterone releasing intra-uterine coil had the highest risk of breast cancer, at 32%.
The number of extra breast cancer cases for every 100,000 women who took the pill for more than five years was eight for those aged 16 to 20 and 265 for those aged 35 to 39. However, the researchers also said that the increased risk of breast cancer should be weighed against the benefits of hormonal contraceptives, including the protection they provide against other forms of female cancer.
It is essential to note that the risk of developing breast cancer because of contraceptive pills remains small. Women should discuss the risks and benefits of different contraceptive options with their healthcare providers. For women with a family history of breast cancer, it may be particularly important to consider the risks and benefits of different contraceptive options in consultation with a healthcare provider.
In conclusion, this study highlights the importance of considering the risks and benefits of hormonal contraceptives for women, particularly those with a family history of breast cancer. Women should discuss their options with their healthcare providers and make informed decisions based on their individual circumstances.
MENAFN27032023000045012476ID1105867464
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.